Home » Stocks » ATHE

Alterity Therapeutics Limited (ATHE)

Stock Price: $1.72 USD 0.06 (3.61%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 62.26M
Revenue (ttm) n/a
Net Income (ttm) -13.46M
Shares Out 894.87M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $1.72
Previous Close $1.66
Change ($) 0.06
Change (%) 3.61%
Day's Open 1.66
Day's Range 1.62 - 1.76
Day's Volume 317,110
52-Week Range 0.36 - 3.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 4 weeks ago

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, ...

Pulse2 - 2 months ago

As of 1:46 PM ET, the stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) (ASX: ATH) is trading up 153.48% at $2.92 (up from the previous close of $1.15). Why is this happening?

InvestorPlace - 2 months ago

Alterity Therapeutics (ATHE) news for Monday includes approval of a new patent protecting its drugs pushing ATHE stock higher. The post Alterity Therapeutics News: 8 Things for ATHE Stock Inve...

Benzinga - 2 months ago

Shares of Alterity Therapeutics Ltd (NASDAQ: ATHE) gap-opened Monday's session higher and are sustaining the gains. What Happened: The Australian biopharma said the U.S. Patent and Trademark O...

Market Watch - 2 months ago

The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, af...

PRNewsWire - 2 months ago

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matte...

PRNewsWire - 2 months ago

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling pa...

24/7 Wall Street - 5 months ago

Alterity Therapeutics Ltd. (NASDAQ: ATHE) stock more than doubled on Tuesday after the company announced new data for its lead drug candidate ATH434.

Market Watch - 5 months ago

Shares of Alterity Therapeutics Ltd. ATHE, -7.53% nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will...

Benzinga - 5 months ago

The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.

PRNewsWire - 5 months ago

Highlights: FDA provides guidance for ATH434 development pathway Company compliant with minimum NASDAQ price End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on...

Benzinga - 6 months ago

Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.

24/7 Wall Street - 6 months ago

Alterity Therapeutics Ltd. (NASDAQ: ATHE) says it has received an update from the U.S.

About ATHE

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, A... [Read more...]

Industry
Biotechnology
Founded
1997
CEO
Geoffrey Kempler
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
ATHE
Full Company Profile

Financial Performance

Financial Statements